ASCO Gastrointestinal Cancers Symposium

Bild/Picture® shutterstock.com

  • PS01 Session 1 - Clinical Indications
  • PS02 Session 2 - New Clinical Data and Trial Pipeline
  • PS03 Session 3 - Next-Gen CAR-T Therapy
  • PS04 Session 4 - CAR-T in Oncology
  • PS06 Session 6 - New CAR-T Indications
  • PS07 Session 7 - CAR-T: New Standard of Care in Lymphoma?
  • PS08 Session 08 - Clinical management

PS01 Session 1 - Clinical Indications

Summary of the presentation with more than 20 direct links to the papers mentioned in the presentation DOWNLOAD

----------------------------------------------------------------------------------------------------------------------------

CONCLUSIONS

  • The introduction of CART cell therapy has revolutionized th of patients with B-Cell NHL
  • Excellent results in phase II pivotal prospective clinical trials
  • Real world data in both EU and US replicate results of PCT
  • Identification of prognostic factors
  • New indications (diseases, early stages) will be coming soon
Summary of the presentation with more than 20 direct links to the papers mentioned in the presentation DOWNLOAD
----------------------------------------------------------------------------------------------------------------------------

CONCLUSIONS

  • CLL among the first diseases treated with CAR-T, but still no approved product
  • CAR-T can overcome the T cell defects seen in this disease and lead in some cases to durable responses
  • Immune modulators to enhance T cell function are being explored and most developed with lbrutinib
  • NK and other cell types being explored
Summary of the presentation with more than 20 direct links to the papers mentioned in the presentation DOWNLOAD
----------------------------------------------------------------------------------------------------------------------------

Conclusions

  • The first CART cell product targeting BCMA was approved in the US/EU /Abecma
    • ide-cel) in 2021 and a second BCMA CART cell product (cilta-cel) will be approved for r/r MM probably in 2022
  • CART cell therapy can induce ORR up to 100% and a CR beyond 80% in patients with r/r MM (with a median of 6 lines of prior therapy) and a PFS of > 2 years

In The Future:

  • CART therapy will potentially become a part of the first-line therapy for ultra/high risk patients
  • CART therapy will challenge ASCT in TE NDMM
  • CART therapy for earlier lines of therapy also in non-transplant eligible patients (low rate of grade >3 CRS/ICANS)

Summary of the presentation with more than 20 direct links to the papers mentioned in the presentation DOWNLOAD

----------------------------------------------------------------------------------------------------------------------------

This year's meeting covered a wide range of topics. In turn, VJHemOnc did interviews on the following topics such as deep science, translational, clinical and commercial development in the field of CAR-T. See these posts on the VJHemOnc events page

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Gesundheitsorganisationen (z.B. Universitätsspital, Swiss Academy of Multidisciplinary Oncology SAMO), Stiftungen (z.B. SONK St.Gallen Oncology Conferences) beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weiter erhält Oncoletter nicht an inhaltliche Bedingungen geknüpfte Unterstützung von Firmen zur Berichterstattung. Seit der Inbetriebnahme von Oncoletter haben folgende Firmen die Webseite vorübergehend/permanent und in wechselnden Zusammensetzungen (jährlich 4-6) unterstützt: Amgen, BMS, Celgene, GSK, Janssen-Cilag, Lilly, Merck, Mundipharma, Novartis, Pfizer, Roche, Servier.
Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren. Bei ausnahmsweise bezahlten Beiträgen oder Interviews (ausschliesslich on-label) wird der Sponsor im Text oder Abspann aufgeführt.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2022. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close